- apioside
-
- $10.00
-
2023-04-04
- CAS:74639-14-8
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 100kg
- Liquiritin apioside
-
-
2023-02-24
- CAS:74639-14-8
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Liquiritin apioside Basic information |
| Product Name: | Liquiritin apioside | | Synonyms: | 4H-1-Benzopyran-4-one, 2-[4-[(2-O-D-apio-β-D-furanosyl-β-D-glucopyranosyl)oxy]phenyl]-2,3-dihydro-7-hydroxy-, (2S)-;(2S)-2-[4-[(2S,3R,4S,5S,6R)-3-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-7-hydroxy-2,3-dihydrochromen-4-one;Liquiritin apioside-RM;Liquiritin apioside, 10 mM in DMSO;Stachyose glycyrrhizinate;Liquiritin apioside (Standard) | | CAS: | 74639-14-8 | | MF: | C26H30O13 | | MW: | 550.51 | | EINECS: | 000-000-0 | | Product Categories: | | | Mol File: | 74639-14-8.mol |  |
| | Liquiritin apioside Chemical Properties |
| Boiling point | 904.5±65.0 °C(Predicted) | | density | 1.65±0.1 g/cm3 (20 ºC 760 Torr) | | pka | 7.70±0.40(Predicted) | | form | Solid | | color | White to light yellow | | Cosmetics Ingredients Functions | SKIN CONDITIONING | | InChIKey | FTVKHUHJWDMWIR-DWMQJYMWSA-N | | SMILES | O1[C@H]([C@@H]([C@@](C1)(O)CO)O)O[C@H]2[C@@H](O[C@@H]([C@H]([C@@H]2O)O)CO)Oc3ccc(cc3)[C@H]4Oc5c(ccc(c5)O)C(=O)C4 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Liquiritin apioside Usage And Synthesis |
| Uses | Liquiritin Apioside is one of the main active components in Suan-Zao-Ren decoction as a treatment for insomnia. | | Definition | ChEBI: Liquiritin apioside is a member of flavonoids and a glycoside. | | in vivo | Liquiritin apioside (10 μg/μL, intralaryngeal or perineural administration; single dose; 10 min, 20 min) significantly attenuates the apnea, hypertension, and bradycardia responses to the laryngeal chemoreflex (LCR) induced by Capsaicin (HY-10448), hydrochloric acid (HCl), and distilled water (DW) in rat pups, but has no significant effect on the laryngeal mechanoreflex (LMR) induced by air pulse (AP) [1].
Liquiritin apioside (0.01 g/kg, 0.2 g/kg; po; once daily for 10 days) ameliorates DSS-induced colitis in mice, and modulates the gut microbial diversity and composition[2].
| Animal Model: | Laryngeal reflexe study in Sprague-Dawley rat (250-350 g) pups[1] | | Dosage: | 10 μg/μL (diluted in saline)
| | Administration: | Intralaryngeal perfusion for 10 minutes or peri-treatment for 20 minutes, single dose | | Result: | Significantly reduced the apneic responses to CAP, HCl, and DW, as well as attenuated the hypertension and bradycardia responses to these stimuli.
Did not change the cardiorespiratory responses to AP.
Peri-SLN treatment with Liquiritin apioside also suppressed the apnea, hypertension, and bradycardia responses to CAP, HCl, and DW, similar to the effect of intralaryngeal treatment.
|
| Animal Model: | DSS-induced colitis model in C57BL/6 mice (male, 18–22 g, 8–10 weeks)[2] | | Dosage: | 0.01 g/kg, 0.02 g/kg (diluted in saline)
| | Administration: | Oral gavaged for 10 days, once daily | | Result: | Exhibited the same pathological changes as that of the ABX (DSS) group mice, specifically, comparable weight loss, DAI score, colon length, and histology score.
|
|
| | Liquiritin apioside Preparation Products And Raw materials |
|